# AI-Enhanced Wide-Field Endoscopic Fluorescence Mapping of Gastrointestinal Mucosal Permeability in IBD - A Pilot Study in IBD Patients and Controls

> **NCT07546955** · — · NOT_YET_RECRUITING · sponsor: **Hamilton Health Sciences Corporation** · enrollment: 70 (estimated)

## Conditions studied

- Inflammatory Bowel Disease (Crohn's Disease; Ulcerative Colitis)
- NON-IBD

## Interventions

- **DIAGNOSTIC_TEST:** Artificial Intelligence-Enhanced Wide-Field Mucosal Permeability Mapping

## Key facts

- **NCT ID:** NCT07546955
- **Lead sponsor:** Hamilton Health Sciences Corporation
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2027-02-01
- **Final completion:** 2027-02-01
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07546955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07546955, "AI-Enhanced Wide-Field Endoscopic Fluorescence Mapping of Gastrointestinal Mucosal Permeability in IBD - A Pilot Study in IBD Patients and Controls". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07546955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*